Home » Topics » Neurology/psychiatric, BioWorld Science

Neurology/psychiatric, BioWorld Science
RSS

New treatment strategy for Parkinson's disease introduced

Sep. 13, 1996

New formulation of selegiline

Sep. 13, 1996

Dopaminergic agents claimed by Sandoz

Sep. 13, 1996

A major breakthrough in the treatment of schizophrenia

Sep. 13, 1996

New compounds from Roche with affinity for benzodiazepine receptors

Sep. 13, 1996

Merck & Co. synthesizes dopamine D4 receptor ligands

Sep. 13, 1996

Divestment of antimigraine treatment from Glaxo Wellcome to Zeneca

Sep. 13, 1996

Controlled-release oral analgesic formulation claimed by Euroceltique

Sep. 13, 1996

Chiron describes a new opiate receptor ligand

Sep. 13, 1996

Delta-opioid agonists for pain

Sep. 13, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...